Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(03): 172-182
DOI: 10.4103/sajc.sajc_25_19
Letter to the Editor

Immunotherapy-induced acute pulmonary thromboembolism: A case report

Waseem Abbas
Department of Medical Oncology, Max Institute of Cancer Care, Shalimar Bagh, Delhi, India
Department of Medical Oncology, Max-Super Speciality Hospital, Shalimar Bagh, Delhi, India
,
Gaurav Dixit
Department of Medical Oncology, Max Institute of Cancer Care, Shalimar Bagh, Delhi, India
Department of Medical Oncology, Max-Super Speciality Hospital, Shalimar Bagh, Delhi, India
,
Ranga Raju Rao
Department of Medical Oncology, Max Institute of Cancer Care, Shalimar Bagh, Delhi, India
Department of Medical Oncology, Max-Super Speciality Hospital, Shalimar Bagh, Delhi, India
,
Vineet Govinda Gupta
Department of Medical Oncology, Max Institute of Cancer Care, Shalimar Bagh, Delhi, India
Department of Medical Oncology, Max-Super Speciality Hospital, Shalimar Bagh, Delhi, India
,
Swati Popli
Department of Medical Oncology, Max Institute of Cancer Care, Shalimar Bagh, Delhi, India
Department of Medical Oncology, Max-Super Speciality Hospital, Shalimar Bagh, Delhi, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
21 December 2020

© 2019. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 2017;545:60-5.
  • 2 Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375:1749-55.
  • 3 Tsukamoto J, Monteiro M, Vale S, Lemos C, Scarpelli T, Carvalho L, et al. Thromboembolic events related to treatment with checkpoint inhibitors: Report of two cases. Case Rep Oncol 2018;11:648-53.
  • 4 Boutros C, Scoazec JY, Mateus C, Routier E, Roy S, Robert C, et al. Arterial thrombosis and anti-PD-1 blockade. Eur J Cancer 2018;91:164-6.
  • 5 Ibrahimi S, Machiorlatti M, Vesely SK, Malla M. Incidence of vascular thromboembolic events in patients receiving immunotherapy: A single institution experience. Blood 2017;130:4864.
  • 6 Fournel L, Arrondeau J, Boudou-Rouquette P, Girault F, Revel MP. Effect of nivolumab therapy on pulmonary artery. J Clin Oncol 2017;35 Suppl 15.
  • 7 Kunimasa K, Nishino K, Kimura M, Inoue T, Tamiya M, Kumagai T, et al. Pembrolizumab-induced acute thrombosis: A case report. Medicine (Baltimore) 2018;97:e10772.
  • 8 Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006;118:555-68.
  • 9 Varki A. Trousseau's syndrome: Multiple definitions and multiple mechanisms. Blood 2007;110:1723-9.